{
  "id": 1769615771046,
  "seqId": 157,
  "title": "Mastering Anti-VEGF Therapy: From Mechanism to Practice",
  "summary": "Anti-vascular endothelial growth factor (VEGF) therapy is a cornerstone of medical retina, targeting VEGF-A to reduce vascular permeability and halt pathologic angiogenesis. This comprehensive guide outlines the pharmacological mechanisms, clinical trial evidence, NICE guidelines, and precise surgical protocols for intravitreal administration.",
  "date": "2026-01-28T15:56:11.046Z",
  "data": {
    "title": "Mastering Anti-VEGF Therapy: From Mechanism to Practice",
    "summary": "Anti-vascular endothelial growth factor (VEGF) therapy is a cornerstone of medical retina, targeting VEGF-A to reduce vascular permeability and halt pathologic angiogenesis. This comprehensive guide outlines the pharmacological mechanisms, clinical trial evidence, NICE guidelines, and precise surgical protocols for intravitreal administration.",
    "summary_illustration": "<svg viewBox='0 0 100 100' xmlns='http://www.w3.org/2000/svg'><circle cx='50' cy='50' r='45' fill='none' stroke='hsl(215, 90%, 45%)' stroke-width='2'/><circle cx='50' cy='50' r='15' fill='hsl(215, 90%, 45%)' opacity='0.2'/><path d='M30 50 Q50 20 70 50 Q50 80 30 50' fill='none' stroke='hsl(215, 90%, 45%)' stroke-width='2'/><circle cx='50' cy='50' r='5' fill='hsl(215, 90%, 45%)'/><line x1='75' y1='25' x2='60' y2='40' stroke='hsl(215, 90%, 45%)' stroke-width='2'/><path d='M70 20 L80 30' stroke='hsl(215, 90%, 45%)' stroke-width='2'/></svg>",
    "sections": [
      {
        "title": "Core Mechanism of Action",
        "icon": "settings_input_component",
        "type": "mindmap",
        "layout": "full_width",
        "color_theme": "blue",
        "content": {
          "center": "VEGF-A (VEGF)",
          "branches": [
            "Induces angiogenesis (developmental & pathological)",
            "Increases vascular permeability",
            "Triggers inflammation",
            "Anti-VEGF Result: Resolution of intraretinal/subretinal fluid",
            "Anti-VEGF Result: Restoration of normal retinal architecture",
            "Anti-VEGF Result: Halts progression of pathologic neovascularization"
          ]
        }
      },
      {
        "title": "The Pharmacological Lineup",
        "icon": "medication",
        "type": "table",
        "layout": "full_width",
        "color_theme": "purple",
        "content": {
          "headers": [
            "Drug",
            "Classification",
            "Mechanism/Specifics",
            "Clinical Status"
          ],
          "rows": [
            [
              "Pegaptanib",
              "Pegylated aptamer",
              "Selective VEGF inhibitor (VEGF-165 isoform)",
              "Less effective; no longer in widespread use."
            ],
            [
              "Ranibizumab",
              "Humanized monoclonal antibody fragment",
              "Binds ALL isoforms of VEGF-A.",
              "Licensed for multiple indications."
            ],
            [
              "Bevacizumab",
              "Humanized monoclonal antibody",
              "Derived from the same antibody as ranibizumab.",
              "Common practice (Off-label)."
            ],
            [
              "Aflibercept",
              "‘Fusion’ protein (Decoy receptor)",
              "Higher affinity than others; binds VEGF-A + PlGF 1 and 2.",
              "Licensed for multiple indications."
            ]
          ]
        }
      },
      {
        "title": "Evidence: Wet AMD (Neovascular AMD)",
        "icon": "visibility",
        "type": "chart",
        "layout": "half_width",
        "color_theme": "green",
        "content": {
          "type": "bar",
          "data": [
            {
              "label": "Ranibizumab Gain ≥15 Letters (MARINA/ANCHOR)",
              "value": 33
            },
            {
              "label": "Ranibizumab Avoid Loss ≥15 Letters",
              "value": 95
            },
            {
              "label": "Aflibercept Gain ≥15 Letters (VIEW 1/2)",
              "value": 30
            },
            {
              "label": "Aflibercept Avoid Loss ≥15 Letters",
              "value": 95
            }
          ]
        }
      },
      {
        "title": "Comparative Trials: Wet AMD",
        "icon": "compare_arrows",
        "type": "plain_text",
        "layout": "half_width",
        "color_theme": "blue",
        "content": "CATT and IVAN studies: Bevacizumab (1.25mg/0.05mL) demonstrated similar efficacy to ranibizumab. However, OCT-guided 'as-required' (PRN) retreatment regimens resulted in less gain in VA, whether started at enrolment or after 1 year of monthly treatment."
      },
      {
        "title": "Evidence: Diabetic Macular Oedema (DMO)",
        "icon": "bloodtype",
        "type": "key_point",
        "layout": "full_width",
        "color_theme": "yellow",
        "content": [
          "Ranibizumab (RISE Trial): 44.8% gained ≥15 letters with 0.3mg monthly (vs 18.1% sham).",
          "Ranibizumab (RIDE Trial): 33.6% gained ≥15 letters with 0.3mg monthly (vs 12.3% sham).",
          "Laser requirement: Ranibizumab-treated patients required significantly fewer macular laser procedures.",
          "Aflibercept (VISTA/VIVID): Mean gain of 10 letters at 3 years.",
          "DRCRNet (1 Year): All drugs gave 10-12 letter improvement; Aflibercept superior in poor starting VA.",
          "DRCRNet (2 Year): Ranibizumab and Aflibercept outcomes were similar."
        ]
      },
      {
        "title": "Evidence: Retinal Vein Occlusion (RVO)",
        "icon": "biotech",
        "type": "table",
        "layout": "full_width",
        "color_theme": "green",
        "content": {
          "headers": [
            "Drug",
            "Study",
            "Indication",
            "Key Result (≥15 Letter Gain)"
          ],
          "rows": [
            [
              "Ranibizumab",
              "CRUISE",
              "CRVO",
              "47.5% (vs 16.9% sham)"
            ],
            [
              "Ranibizumab",
              "BRAVO",
              "BRVO",
              "61.1% (vs 28.8% sham)"
            ],
            [
              "Aflibercept",
              "COPERNICUS",
              "CRVO",
              "55.3%"
            ],
            [
              "Aflibercept",
              "GALILEO",
              "CRVO",
              "60.2%"
            ],
            [
              "Aflibercept",
              "VIBRANT",
              "BRVO",
              "57.1% (at 1 year)"
            ]
          ]
        }
      },
      {
        "title": "Evidence: Myopia-associated CNV",
        "icon": "remove_red_eye",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "purple",
        "content": [
          "RADIANCE Study (Ranibizumab): Superior to PDT. Gain of 10.5-10.6 letters at 3mo (vs 2.2 PDT). At 12mo: 13.8-14.4 letters (vs 9.3 PDT).",
          "MyRROR Study (Aflibercept): 12.1 letter improvement at 24wk (vs -2.0 sham). At 48wk: 13.5 letters total gain."
        ]
      },
      {
        "title": "NICE Guidelines: Wet AMD & CNV",
        "icon": "gavel",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "Ranibizumab (2008) / Aflibercept (2013) recommended for Wet AMD if:",
          "• BCVA between 6/12 and 6/96.",
          "• No permanent structural damage to central fovea.",
          "• Lesion size ≤12 disc areas.",
          "• Evidence of recent disease progression.",
          "Pegaptanib: NOT recommended for wet AMD.",
          "Pathological Myopia (CNV): Ranibizumab approved (2013); Aflibercept (appraisal expected Jan 2018)."
        ]
      },
      {
        "title": "NICE Guidelines: DMO, RVO, & Steroids",
        "icon": "rule",
        "type": "plain_text",
        "layout": "full_width",
        "color_theme": "yellow",
        "content": "DMO: Ranibizumab (2013) / Aflibercept (2015) if Central Retinal Thickness (CRT) ≥400 microns and manufacturer discount provided. RVO: Ranibizumab (2013), Aflibercept CRVO (2014), Aflibercept BRVO (2016). Steroid Implants: Dexamethasone for RVO (2011) and DMO in pseudophakic eyes (2015) if non-responsive to other treatments. Fluocinolone acetonide (2013) for DMO in pseudophakic eyes not responding to other treatments."
      },
      {
        "title": "Intravitreal Injection: Pre-Procedure",
        "icon": "clinical_notes",
        "type": "process",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "1. Discuss procedure and take informed consent.",
          "2. Explain purpose: maintain vision and potential improvement.",
          "3. Warn of risks and need for multiple injections.",
          "4. Bevacizumab specific: Explain off-label status and licensed alternatives for AMD.",
          "5. Setting: Theatre or dedicated clean room (enclosed, no interruptions).",
          "6. Environmental checks: Illumination, washable floor, dust-free ceiling."
        ]
      },
      {
        "title": "Intravitreal Injection: Preparation",
        "icon": "inventory_2",
        "type": "process",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "1. Confirm consent and correct eye.",
          "2. Measure IOP.",
          "3. Ensure adequate dilation.",
          "4. Instil topical anaesthesia.",
          "5. Set up equipment trolley.",
          "6. Verify all drugs and post-injection antibiotics are available."
        ]
      },
      {
        "title": "Surgical Procedure Steps",
        "icon": "medical_services",
        "type": "process",
        "layout": "full_width",
        "color_theme": "green",
        "content": [
          "Step 1: Wash hands and don sterile gloves (full gowning unnecessary).",
          "Step 2: Instil topical anaesthetic and 5% povidone iodine onto ocular surface.",
          "Step 3: Clean periocular area with povidone iodine; drape and insert lid speculum.",
          "Step 4: Supplement anaesthesia if needed (Subconjunctival/Sub-Tenon's lidocaine 1%).",
          "Step 5: Prepare syringe immediately prior; expel air; maintain aseptic technique.",
          "Step 6: Mark site: 3.0–3.5mm (pseudophakic) or 3.5–4mm (phakic) posterior to limbus.",
          "Step 7: Insert 27–30g needle (1/2–5/8in) perpendicularly toward centre of globe.",
          "Step 8: Inject 0.05mL volume; remove needle; use cotton-tipped applicator for reflux/counterpressure.",
          "Step 9: Instil preservative-free topical antibiotic (e.g., chloramphenicol 0.5%)."
        ]
      },
      {
        "title": "Post-Injection & Follow-up",
        "icon": "history",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "purple",
        "content": [
          "Test gross VA immediately post-injection.",
          "Check central retinal artery patency (if acuity unsatisfactory).",
          "IOP check (often omitted unless specific concern).",
          "Antibiotics: Chloramphenicol 0.5% 4×/d for ≥3 days (varies by centre).",
          "Review in clinic according to specific retreatment regimen."
        ]
      },
      {
        "title": "Signs of Disease Activity (Wet AMD)",
        "icon": "warning",
        "type": "remember",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": {
          "mnemonic": "DAFA",
          "explanation": "D: Deterioration in VA; A: Abnormal retinal thickness/Fluid on OCT (Intraretinal, subretinal, or sub-RPE); F: Fluorescein angiography leakage (CNV); A: Appearance of new intraretinal or subretinal haemorrhage."
        }
      },
      {
        "title": "Side Effects & Complications",
        "icon": "report_problem",
        "type": "red_flag",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "Endophthalmitis (<0.1%)",
          "Retinal detachment",
          "Lens damage/cataract",
          "Raised IOP",
          "Conjunctival haemorrhage",
          "Vitreous floaters (expected post-procedure)",
          "Intraocular inflammation",
          "Eye pain",
          "Visual loss"
        ]
      },
      {
        "title": "Patient Contraindications & Advice",
        "icon": "error",
        "type": "red_flag",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "CONTRAINDICATION: Allergy to any drug components.",
          "CONTRAINDICATION: Ocular and periocular infections.",
          "ADVICE: Explain endophthalmitis warning symptoms clearly.",
          "ADVICE: Advise that floaters post-procedure are normal."
        ]
      }
    ],
    "chapterId": "medical_retina"
  },
  "chapterId": "medical_retina",
  "_newlyImported": 1769615771046,
  "communityId": "sub_1769614749293_k5acjeivm5o4d7",
  "communityAuthor": "hh",
  "communityDate": "2026-01-28T15:39:09.293Z",
  "_serverSynced": true
}